In March 2024, Regor Therapeutics Group, a clinical-stage global biopharmaceutical company utilizing a cutting-edge drug discovery engine and a differentiated clinical development pipeline, announced the initiation of its Phase 2 trial of the highly selective oral GLP-1 agonist RGT-075
DM: Data curation, Formal Analysis, Software, Writing review & editing
The vote on adding semax, for migraines as well as the neurological conditions cerebral ischemia and trigeminal neuralgia, was 8-5
Plasmid constructs Plasmids expressing EGFP, FLAG- or HA-tagged mouse Mak and Ick, FLAG-tagged EGFP, mouse IFT57, IFT88, IFT140, BBS8, and Ick-KD, and HA-tagged human ICK were previously constructed (33, 52, 99)